Review article · 3 May 2019
Conference abstractPublished 8 Sep 2014
CAPA program management via the DMAIC methodology
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Life sciences companies are facing increasing pressure from regulatory bodies, to take a proactive approach for managing non-conformity, process deviations, and critical observations in relation to their defined quality procedures. Approximately 30% to 50% of all FDA-483 citations in FDA regulated industries are related to problems with corrective action & preventive action (CAPA) processes. CAPA is one such process that has become a formal requirement by regulatory authorities for categorizing the various types of issues a life sciences company may encounter. The CAPA process presented here is based on the define, measure, analyze, improve, and control (DMAIC) framework, which can improve quality systems performance. DMAIC refers to a data-driven improvement cycle used for improving, optimizing and stabilizing business processes and designs. The DMAIC improvement cycle is the core process used to drive six sigma projects. The DMAIC framework is a business methodology that helps track down and mitigate the root causes of defects. Using DMAIC, you define a problem, measure performance of an area or process, analyze the process, make improvements based on the analysis, and control the amended process. A DMAIC based CAPA system must contain critical and key functionality, which individually and collectively, must be used to properly manage all deviations or non-conformities while helping the company to manage, monitor and document its efforts to comply with FDA regulations as well as international regulatory authorities, and to help solve the CAPA processes conundrum, which is how to maximize efficiencies and minimize costs while continuously increasing product quality.
Subjects
Pharmaceutical SciencesAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Conference abstract · 25 Sep 2014
Effective CAPA Program, A valuable tool in quality improvement
Conference abstract · 12 Nov 2013
Effective integration of quality risk management into the CAPA system
Conference abstract · 12 Nov 2013
CAPA and risk management
Conference abstract · 28 Jan 2022
Synthesis of New Scaffolds of Isoxazolidine and Isoxazoline Derivatives using Some Novel Class of Nitrones via 1,3-Dipolar Cycloaddition Reaction using Greener Methodologies and Biological activities of the Cycloadducts
More from this journal
The newest in Pharmaceutical Regulatory Affairs: Open Access.
Article · 13 Feb 2026
Regulatory Scenario of Pharmaceuticals during COVID-19 Pandemic in India
Article · 11 Feb 2026
EU GMP Annex 1 of 2022: A View in Depth
Article · 11 Feb 2026
Standard Formats Used in Drug Regulatory Submissions and Software Used
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalPharmaceutical Regulatory Affairs: Open Access
- SubjectPharmaceutical Sciences
- BylineArticles whose byline prints “Roger E Gould”

